Despite of the extensive research, the prognostic and predictive power and thus the clinical utility of KRAS oncogenic mutations in lung adenocarcinoma has not yet been defined for over a decade5, 17, 35, 36. This evidence concerns the gene KRAS and lung adenocarcinoma.